

[Alerts and Recalls](#)

Generic Name (Trade Name—Company)

October 4, 2018

No generic name

(NeoRelief for Muscle Cramping and Restlessness Topical Gel—BioLyte Laboratories/King Bio Inc.)

Topical gel recalled due to possible microbial contamination

Uses/Notes

BioLyte Laboratories is voluntarily [recalling](#) lot numbers 1138, 1139, 1146, and 1160 of NeoRelief for Muscle Cramping and Restlessness Topical Gel to the retail and consumer level.

King Bio Inc., a manufacturer of some of the active ingredients in this product, has been found to have some water contamination issues that could have affected this product. King Bio has issued a recall of these active ingredients in BioLyte's lot specific product.

Administration or use of drug products with microbial contamination could result in increased infections that may require medical intervention or that could be life threatening to certain individuals.

Lot Number	Expiry	UPC	Size	Package type
1138	1/31/2020	3583680022 021	oz	white airless pump bottle
1139	1/31/2020	3583680022 021	oz	white airless pump bottle
1146	3/29/2020	3583680024 045	ml	4" x 2" mylar foil pack
1160	10/10/2019	3583680022 021	oz	white airless pump bottle

BioLyte Laboratories is notifying its retail partners, distributors, and customers by letter and is arranging for return and replacement of the recalled product.

To date, there have been no reports of illness or injury due to use of this product.

Source URL:

<http://personify.pharmacist.com/alerts-and-recalls/topical-gel-recalled-due-possible-microbial-contamination>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.